AstraZeneca said Baxfendy (baxdrostat) was recommended for EU approval for adults with uncontrolled hypertension. If approved, it would be the EU’s first and only aldosterone synthase inhibitor; two Phase III trials showed reductions of 15.7 mmHg and 16.6 mmHg in systolic blood pressure.
AZN · Astrazeneca PLC
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
AstraZeneca’s Imfinzi plus EV (enfortumab vedotin) received US approval for perioperative treatment of adults with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based chemotherapy. The VOLGA Phase III trial showed 49% lower recurrence risk and 42% lower death risk.
AstraZeneca PLC reported that Klygefa (gefurulimab) received European Union (EU) approval as an add-on to standard therapy for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, based on positive PREVAIL Phase III trial results.
AstraZeneca PLC admitted 11,948 further securities to the London Stock Exchange - Main Market, bringing total securities in issue to 1,551,065,237; they were issued between 1 October 2026 to 31 October 2026 under employee share schemes.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AZN
this stock
Astrazeneca PLC
|
$285.40B | — | — | — | 0.2% |
|
LLY
ELI LILLY & Co
|
$1.35T | +33.2% | +44.7% | 46.5 | 0.8% |
|
JNJ
Johnson & Johnson
|
$680.19B | +36.5% | +6.0% | 42.9 | 0.7% |
|
ABBV
AbbVie Inc.
|
$520.65B | +28.9% | +8.6% | 50.7 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$356.13B | +37.2% | +1.3% | 148.9 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 101
AstraZeneca’s Imfinzi plus EV (enfortumab vedotin) received US approval for perioperative treatment of adults with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based chemotherapy. The VOLGA Phase III trial showed 49% lower recurrence risk and 42% lower death risk.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AZN | -2.8% | +12.2% | -0.9% | -1.4% | +0.1% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -1.2% | +15.7% | +0.5% | +0.7% | -8.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.